SAT0341 Assessment of Damage in Behcet's Disease: Do We Need A Specific Damage Index?. (15th July 2016)

• Record Type: Journal Article
• Authors: Unal, A.U.; Yildirim, H.G.; Cikikci, C.; Ozen, G.; Inanc, N.; Atagunduz, P.; Ergun, T.; Direskeneli, H.
• Is Part Of: Annals of the rheumatic diseases. Volume 75(2016)Supplement 2
• Page Start: 790
• Page End: 791
• Publication Date: 2016-07-15
• Subjects: Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2016-eular.4777
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Background: Behcet's Disease (BD) is a systemic inflammatory disease characterized by involvement of vessels of any size and type. In the course of systemic vasculitis, it is important to distinguish disease activity from disease damage to prevent unnecessary immunosuppression. Additionally damage is an important surrogate for long-term outcome in vasculitis. Although a well-established validated damage index, "vasculitis damage index" (VDI) is available for vasculitis, its performance in determining the damage in BD has never been assessed. Objectives: To assess the damage in BD by using VDI, to determine whether VDI covers all BD-associated damage and lastly to develop a preliminary BD-specific damage index with the obtained data. Methods: A total of 139 consecutive patients with BD (F/M: 58/81, mean age 38.9±10.9 yrs, disease duration 9.5±7.4 yrs) from a single center were evaluated for damage in a cross-sectional study using the VDI. Considering the patients data and items of VDI with further literature search for BD-specific damages, new items (detailed cardiovascular, ocular, and vascular involvement-, particularly venous disease-related damages) were added to VDI. This modified VDI (Behcet's Disease-VDI [B-VDI]) was also scored in all patients. Results: Seventy seven patients (55.4%) had major organ involvement and 105 (75.5%) patients were on immunosupressive (IS) treatment (Table 1 ). The mean VDI score was 0.3±0.7 and the majority of the patients had score "0" ("0" in 107 [77%], "1" in 22 [15.8%], "2" in 7 [5%], "3" in 1 [0.7%], and "4" in 2 [1.4%] patients). The mean B-VDI score was 0.6±1.1 ("0" in 92 [66.2%], "1" in 25 [18%], "2" in 13 [9.4%], "3" in 4 [2.9%] and "4" in 3 [2.2%] patients, "5" in 1 [0.7%], and "6" in 1 [0.7%] patient) and was significantly higher than VDI (p<0.001). The main difference between VDI and B-VDI was in vascular (0.05±0.2 vs 0.3±0.6, p<0.001) damage items. Both VDI and B-VDI scores were significantly higher in patients with major organ involvement compared to mucocutaneous BD. Both scores also positively correlated with the age, disease duration and total duration of IS treatment. When individual organ items were evaluated, damage in patients with major organ involvement was observed to be predominantly associated with ocular and vascular involvements. Although VDI-eye and B-VDI-eye scores were not significantly different (both 0.3±0.6, p=0.32), B-VDI-vascular scores were significantly higher than VDI-vascular scores both in the entire cohort and in patients with major organ involvement (0.6±0.8 vs 0.1±0.3, p<0.001). Conclusions: Both VDI and B-VDI capture reliable data on damage among patients with BD. However, VDI does not cover all vascular involvement-related damages of BD. Therefore addition of new items, especially about vascular damage, to VDI will provide more comprehensive assessment of damage in BD. Further prospective follow-up is required to determine the prognostic value of these damage indices in BD. Disclosure of Interest: None declared